Sign In to Follow Application
View All Documents & Correspondence

Novel Anti Human Ngf Antibody

Abstract: [Problem] To provide: an anti human NGF antibody which is reduced in the influence on fetuses and the risk of adverse side effects including thrombosis while keeping a high neutralizing activity and which has excellent safety or an antigen binding fragment thereof; and a means for preventing or treating various diseases for which human NGF is involved in the development of a disease state which utilizes the antibody or an antigen binding fragment thereof. [Solution] An Fab fragment of an anti human NGF antibody which comprises a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 4.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
24 January 2014
Publication Number
14/2015
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
patent@depenning.com
Parent Application
Patent Number
Legal Status
Grant Date
2020-07-07
Renewal Date

Applicants

Astellas Pharma Inc.
3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411

Inventors

1. KAMOHARA Masazumi
c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411
2. TANAKA Hirotsugu
c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411
3. KOYA Yukari
c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411
4. TAKASAKI Jun
c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411
5. YONEZAWA Atsuo
c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411
6. YOSHIMI Eiji
c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411

Specification

[Claim 1] An anti-human NGF antibody Fab5 fragment comprising:
a heavy-chain variable region consisting of an amino acid sequence shown by SEQ
IDNO:6;and
a light-chain variable region consisting of an amino acid sequence shown by SEQ
IDNO:4.
[Claim 2] The Fab' fragment according to Claim 1, wherein a heavy-chain constant
region of the Fab5 fragment is a human Igyl constant region.
[Claim 3] The Fab5 fragment according to Claim 1, wherein a light-chain constant
region of the Fab' fragment is a human IgK constant region.
[Claim 4] The Fab' fragment according to Claim 1, wherein the heavy-chain
constant region of the Fab' fragment is the human Igyl constant region, and the light-chain constant region of the Fab3 fragment is the human IgK constant region.
[Claim 5] The Fab' fragment according to Claim 1, comprising;
a heavy-chain fragment consisting of an amino acid sequence shown by SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:16; and
a light chain consisting of an amino acid sequence shown by SEQ ID NO: 12.
[Claim 6] The Fab' fragment according to any one of Claims I to 5, wherein the Fab'
fragment is conjugated to polyethylene glycol
[Claim 7] A polynucleotide comprising a sequence that encodes the heavy-chain
fragment of the Fab' fragment according to Claim 1.
[Claim 8] A polynucleotide comprising a sequence that encodes the light chain of
the Fab' fragment according to Claim 1.
[Claim 9] An expression vector comprising the polynucleotide according to Claim 7
and/or Claim 8=
[Claim 10] A host cell transformed with the expression vector according to Claim 9.

[Claim 11] The host cell according to Claim 105 which is selected from a group
consisting of the following (a) and (b)s
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain fragment of the Fab' fragment according to Claim 1 and a polynucleotide comprising sequence that encodes the light chain of the Fab3 fragment; and
(b) a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain fragment of the Fab' fragment according to Claim 1 and with an expression vector comprising a polynucleotide comprising a sequence that encodes the light chain of the Fab' fragment.
[Claim 12] Amethodof producing the anti-human NGF antibody Fab5 fragment according to Claim 1, comprising expressing an anti-human NGF antibody Fab' fragment by culturing the host cell according to Claim 10 or 11.

Documents

Application Documents

# Name Date
1 614-CHENP-2014-Abstract_Granted 340768_07-07-2020.pdf 2020-07-07
1 Y04-305461-IN_sequence listing.txt 2014-02-05
2 614-CHENP-2014-Claims_Granted 340768_07-07-2020.pdf 2020-07-07
2 GPA.pdf 2014-02-05
3 F5.pdf 2014-02-05
3 614-CHENP-2014-Description_Granted 340768_07-07-2020.pdf 2020-07-07
4 F3.pdf 2014-02-05
4 614-CHENP-2014-Drawings_Granted 340768_07-07-2020.pdf 2020-07-07
5 614-CHENP-2014.pdf 2014-02-05
5 614-CHENP-2014-IntimationOfGrant07-07-2020.pdf 2020-07-07
6 614-CHENP-2014-Marked up Claims_Granted 340768_07-07-2020.pdf 2020-07-07
6 262-2014-COMPLETE SPECIFICATION.pdf 2014-02-05
7 614-CHENP-2014-PatentCertificate07-07-2020.pdf 2020-07-07
7 614-CHENP-2014 FORM-3 07-07-2014.pdf 2014-07-07
8 614-CHENP-2014-2. Marked Copy under Rule 14(2) [30-06-2020(online)].pdf 2020-06-30
8 614-CHENP-2014 FORM-1 07-07-2014.pdf 2014-07-07
9 614-CHENP-2014 CORRESPONDENCE OTHERS 07-07-2014.pdf 2014-07-07
9 614-CHENP-2014-Response to office action [30-06-2020(online)].pdf 2020-06-30
10 614-CHENP-2014 FORM-13 16-09-2014.pdf 2014-09-16
10 614-CHENP-2014-Retyped Pages under Rule 14(1) [30-06-2020(online)].pdf 2020-06-30
11 614-CHENP-2014 OTHER PATENT DOCUMENT 16-09-2014.pdf 2014-09-16
11 614-CHENP-2014-certified copy of translation (MANDATORY) [04-03-2019(online)].pdf 2019-03-04
12 614-CHENP-2014-CLAIMS [04-03-2019(online)].pdf 2019-03-04
12 614-P-2014 (Marked up copy of claims).pdf 2014-09-26
13 614-CHENP-2014-COMPLETE SPECIFICATION [04-03-2019(online)].pdf 2019-03-04
13 614-P-2014 (Form 13).pdf 2014-09-26
14 614-CHENP-2014-FER_SER_REPLY [04-03-2019(online)].pdf 2019-03-04
14 614-P-2014 (Amended claims).pdf 2014-09-26
15 614-CHENP-2014 FORM-3 28-05-2015.pdf 2015-05-28
15 614-CHENP-2014-FORM 3 [04-03-2019(online)].pdf 2019-03-04
16 614-CHENP-2014 CORRESPONDENCE OTHERS 28-05-2015.pdf 2015-05-28
16 614-CHENP-2014-OTHERS [04-03-2019(online)].pdf 2019-03-04
17 Form 3 [12-06-2017(online)].pdf 2017-06-12
17 614-CHENP-2014-PETITION UNDER RULE 137 [04-03-2019(online)]-1.pdf 2019-03-04
18 614-CHENP-2014-FER.pdf 2018-09-06
18 614-CHENP-2014-PETITION UNDER RULE 137 [04-03-2019(online)].pdf 2019-03-04
19 614-CHENP-2014-certified copy of translation (MANDATORY) [16-11-2018(online)].pdf 2018-11-16
19 Correspondence by Agent_Power of Attorney_26-12-2018.pdf 2018-12-26
20 614-CHENP-2014-FORM-26 [14-12-2018(online)].pdf 2018-12-14
21 614-CHENP-2014-certified copy of translation (MANDATORY) [16-11-2018(online)].pdf 2018-11-16
21 Correspondence by Agent_Power of Attorney_26-12-2018.pdf 2018-12-26
22 614-CHENP-2014-FER.pdf 2018-09-06
22 614-CHENP-2014-PETITION UNDER RULE 137 [04-03-2019(online)].pdf 2019-03-04
23 614-CHENP-2014-PETITION UNDER RULE 137 [04-03-2019(online)]-1.pdf 2019-03-04
23 Form 3 [12-06-2017(online)].pdf 2017-06-12
24 614-CHENP-2014-OTHERS [04-03-2019(online)].pdf 2019-03-04
24 614-CHENP-2014 CORRESPONDENCE OTHERS 28-05-2015.pdf 2015-05-28
25 614-CHENP-2014-FORM 3 [04-03-2019(online)].pdf 2019-03-04
25 614-CHENP-2014 FORM-3 28-05-2015.pdf 2015-05-28
26 614-CHENP-2014-FER_SER_REPLY [04-03-2019(online)].pdf 2019-03-04
26 614-P-2014 (Amended claims).pdf 2014-09-26
27 614-CHENP-2014-COMPLETE SPECIFICATION [04-03-2019(online)].pdf 2019-03-04
27 614-P-2014 (Form 13).pdf 2014-09-26
28 614-CHENP-2014-CLAIMS [04-03-2019(online)].pdf 2019-03-04
28 614-P-2014 (Marked up copy of claims).pdf 2014-09-26
29 614-CHENP-2014 OTHER PATENT DOCUMENT 16-09-2014.pdf 2014-09-16
29 614-CHENP-2014-certified copy of translation (MANDATORY) [04-03-2019(online)].pdf 2019-03-04
30 614-CHENP-2014 FORM-13 16-09-2014.pdf 2014-09-16
30 614-CHENP-2014-Retyped Pages under Rule 14(1) [30-06-2020(online)].pdf 2020-06-30
31 614-CHENP-2014 CORRESPONDENCE OTHERS 07-07-2014.pdf 2014-07-07
31 614-CHENP-2014-Response to office action [30-06-2020(online)].pdf 2020-06-30
32 614-CHENP-2014 FORM-1 07-07-2014.pdf 2014-07-07
32 614-CHENP-2014-2. Marked Copy under Rule 14(2) [30-06-2020(online)].pdf 2020-06-30
33 614-CHENP-2014 FORM-3 07-07-2014.pdf 2014-07-07
33 614-CHENP-2014-PatentCertificate07-07-2020.pdf 2020-07-07
34 262-2014-COMPLETE SPECIFICATION.pdf 2014-02-05
34 614-CHENP-2014-Marked up Claims_Granted 340768_07-07-2020.pdf 2020-07-07
35 614-CHENP-2014-IntimationOfGrant07-07-2020.pdf 2020-07-07
35 614-CHENP-2014.pdf 2014-02-05
36 614-CHENP-2014-Drawings_Granted 340768_07-07-2020.pdf 2020-07-07
36 F3.pdf 2014-02-05
37 F5.pdf 2014-02-05
37 614-CHENP-2014-Description_Granted 340768_07-07-2020.pdf 2020-07-07
38 GPA.pdf 2014-02-05
38 614-CHENP-2014-Claims_Granted 340768_07-07-2020.pdf 2020-07-07
39 Y04-305461-IN_sequence listing.txt 2014-02-05
39 614-CHENP-2014-Abstract_Granted 340768_07-07-2020.pdf 2020-07-07

Search Strategy

1 Captured_20-08-2018.pdf

ERegister / Renewals

3rd: 09 Sep 2020

From 10/08/2014 - To 10/08/2015

4th: 09 Sep 2020

From 10/08/2015 - To 10/08/2016

5th: 09 Sep 2020

From 10/08/2016 - To 10/08/2017

6th: 09 Sep 2020

From 10/08/2017 - To 10/08/2018

7th: 09 Sep 2020

From 10/08/2018 - To 10/08/2019

8th: 09 Sep 2020

From 10/08/2019 - To 10/08/2020

9th: 09 Sep 2020

From 10/08/2020 - To 10/08/2021

10th: 09 Sep 2020

From 10/08/2021 - To 10/08/2022